The clinical outcome of primary refractory (PRF) AML patients is poor and only a minor proportion of patients is rescued by allogenic hematopoietic stem cell transplantation (HSCT). The identification of pre-HSCT variables may help to determine PRF AML patients who can most likely benefit from HSCT. We analyzed PRF AML patients transplanted between 1999 and 2012 from a sibling, unrelated donor or a cord blood unit. Overall, 227 patients from 26 Gruppo Italiano Trapianto di Midollo Osseo e Terapia cellulare centers were included in the analysis. At 3 years, the overall survival was 14%. By multivariate analysis, the number of chemotherapy cycles, (hazard ratio (HR): 1.87; 95% confidence interval (CI): 1.24-2.85; P=0.0028), the percentage of bone marrow or peripheral blood blasts (HR: 1.75; 95% CI: 1.16-2.64; P=0.0078), the adverse cytogenetic (HR: 1.44; 95% CI: 1.00-2.07; P=0.0508) and the age of patients (HR: 1.77; 95% CI: 1.08-2.88; P=0.0223) remained significantly associated with survival. Thus, we set up a new score predicting at 3 years after transplantation, an overall survival probability of 32% for patients with score 0 (no or 1 prognostic factor), 10% for patients with score 1 (2 prognostic factors) and 3% for patients with score 2 (3 or 4 prognostic factors).

Todisco, E., Ciceri, F., Boschini, C., Giglio, F., Bacigalupo, A., Patriarca, F., Donnini, I., Alessandrino, E. P., Arcese, W., Iori, A. P., Marenco, P., Cavattoni, I., Chiusolo, P., Terruzzi, E., Castagna, L., Santoro, A., Bosi, A., Oldani, E., Bruno, B., Bonifazi, F., Rambaldi, A., Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: A retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO), <<BONE MARROW TRANSPLANTATION>>, 2017; 52 (7): 955-961. [doi:10.1038/bmt.2016.325] [http://hdl.handle.net/10807/123866]

Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: A retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO)

Bacigalupo, A.;Chiusolo, P.;
2017

Abstract

The clinical outcome of primary refractory (PRF) AML patients is poor and only a minor proportion of patients is rescued by allogenic hematopoietic stem cell transplantation (HSCT). The identification of pre-HSCT variables may help to determine PRF AML patients who can most likely benefit from HSCT. We analyzed PRF AML patients transplanted between 1999 and 2012 from a sibling, unrelated donor or a cord blood unit. Overall, 227 patients from 26 Gruppo Italiano Trapianto di Midollo Osseo e Terapia cellulare centers were included in the analysis. At 3 years, the overall survival was 14%. By multivariate analysis, the number of chemotherapy cycles, (hazard ratio (HR): 1.87; 95% confidence interval (CI): 1.24-2.85; P=0.0028), the percentage of bone marrow or peripheral blood blasts (HR: 1.75; 95% CI: 1.16-2.64; P=0.0078), the adverse cytogenetic (HR: 1.44; 95% CI: 1.00-2.07; P=0.0508) and the age of patients (HR: 1.77; 95% CI: 1.08-2.88; P=0.0223) remained significantly associated with survival. Thus, we set up a new score predicting at 3 years after transplantation, an overall survival probability of 32% for patients with score 0 (no or 1 prognostic factor), 10% for patients with score 1 (2 prognostic factors) and 3% for patients with score 2 (3 or 4 prognostic factors).
Inglese
Todisco, E., Ciceri, F., Boschini, C., Giglio, F., Bacigalupo, A., Patriarca, F., Donnini, I., Alessandrino, E. P., Arcese, W., Iori, A. P., Marenco, P., Cavattoni, I., Chiusolo, P., Terruzzi, E., Castagna, L., Santoro, A., Bosi, A., Oldani, E., Bruno, B., Bonifazi, F., Rambaldi, A., Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: A retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO), <<BONE MARROW TRANSPLANTATION>>, 2017; 52 (7): 955-961. [doi:10.1038/bmt.2016.325] [http://hdl.handle.net/10807/123866]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/123866
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 17
social impact